Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.

In conclusion, CYD-TDV was shown to maintain efficacy against symptomatic VCD in seropositive participants aged ≥9 years up to six years after the first dose. Persistence of efficacy was also observed in seropositive participants aged 6-8 years.
PMID: 32204943 [PubMed - as supplied by publisher]

Source: Vaccine - March 19, 2020 Category: Allergy & Immunology Authors: Dayan GH, Langevin E, Gilbert PB, Wu Y, Moodie Z, Forrat R, Price B, Frago C, Bouckenooghe A, Cortes M, Noriega F, DiazGranados CA Tags: Vaccine Source Type: research